{
    "id": 23081,
    "fullName": "ALK D1091N",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ALK D1091N lies within the cytoplasmic domain of the Alk protein (UniProt.org). D1091N was observed to increase ERK activation in the presence of agonist antibodies (PMID: 23104988), but is unable to transform cultured cells (PMID: 23104988), and therefore, its effect on Alk protein function is unknown.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 1899,
                    "pubMedId": 23104988,
                    "title": "Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23104988"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 238,
        "geneSymbol": "ALK",
        "terms": [
            "ALK",
            "CD246",
            "NBLST3"
        ]
    },
    "variant": "D1091N",
    "createDate": "06/09/2016",
    "updateDate": "10/27/2019",
    "referenceTranscriptCoordinates": {
        "id": 102007,
        "transcript": "NM_004304",
        "gDna": "chr2:g.29223430C>T",
        "cDna": "c.3271G>A",
        "protein": "p.D1091N",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11449,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alecensa (alectinib) treatment enhanced the cytotoxic effects of Adriamycin (doxorubicin) in a neuroblastoma cell line harboring ALK D1091N, demonstrating increased apoptotic activity and decreased cell viability in culture (PMID: 28455243).",
            "molecularProfile": {
                "id": 23761,
                "profileName": "ALK D1091N"
            },
            "therapy": {
                "id": 5989,
                "therapyName": "Alectinib + Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9400,
                    "pubMedId": 28455243,
                    "title": "The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28455243"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11450,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3463 treatment in a neuroblastoma cell line harboring ALK D1091N resulted in inhibition of colony formation, repression of Pi3k signaling, and induction of apoptosis in culture (PMID: 26786851).",
            "molecularProfile": {
                "id": 23761,
                "profileName": "ALK D1091N"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7594,
                    "pubMedId": 26786851,
                    "title": "Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26786851"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11448,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alecensa (alectinib) treatment in a neuroblastoma cell line harboring ALK D1091N resulted in decreased cell viability, inhibition of colony formation, and inhibition of Pi3k pathway signaling in culture (PMID: 28455243).",
            "molecularProfile": {
                "id": 23761,
                "profileName": "ALK D1091N"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9400,
                    "pubMedId": 28455243,
                    "title": "The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28455243"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11451,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3463 treatment enhanced the cytotoxic effects of Adriamycin (doxorubicin) in a neuroblastoma cell line harboring ALK D1091N, demonstrating increased apoptotic activity and decreased cell viability in culture (PMID: 28455243).",
            "molecularProfile": {
                "id": 23761,
                "profileName": "ALK D1091N"
            },
            "therapy": {
                "id": 5990,
                "therapyName": "AZD3463 + Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9400,
                    "pubMedId": 28455243,
                    "title": "The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28455243"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23761,
            "profileName": "ALK D1091N",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102007,
            "transcript": "NM_004304",
            "gDna": "chr2:g.29223430C>T",
            "cDna": "c.3271G>A",
            "protein": "p.D1091N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}